Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $3.2 million.

  • Akebia Therapeutics' Share-based Compensation rose 9568.65% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year increase of 2883.3%. This contributed to the annual value of $7.8 million for FY2024, which is 1655.04% down from last year.
  • Akebia Therapeutics' Share-based Compensation amounted to $3.2 million in Q3 2025, which was up 9568.65% from $2.7 million recorded in Q2 2025.
  • Akebia Therapeutics' Share-based Compensation's 5-year high stood at $6.9 million during Q2 2022, with a 5-year trough of $1.5 million in Q4 2023.
  • Over the past 5 years, Akebia Therapeutics' median Share-based Compensation value was $3.0 million (recorded in 2022), while the average stood at $3.5 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first plummeted by 5021.37% in 2023, then surged by 9568.65% in 2025.
  • Over the past 5 years, Akebia Therapeutics' Share-based Compensation (Quarter) stood at $4.6 million in 2021, then tumbled by 34.4% to $3.0 million in 2022, then tumbled by 50.21% to $1.5 million in 2023, then rose by 12.09% to $1.7 million in 2024, then skyrocketed by 89.81% to $3.2 million in 2025.
  • Its Share-based Compensation stands at $3.2 million for Q3 2025, versus $2.7 million for Q2 2025 and $2.2 million for Q1 2025.